MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:10Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 15:		Line 15:
	\| legal = Rx-only in US		\| legal = Rx-only in US
	\| mechanism = Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares.		\| mechanism = Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares.
	\| intro = Prazosin is best known in psychiatry as an off-label treatment for PTSD nightmares — it suppresses noradrenergic hyperactivity at night and reduces both nightmare frequency and severity in many patients. Originally an antihypertensive; now more often prescribed in mental health than cardiology. First-dose orthostatic hypotension is well-known — start at 1 mg HS and titrate slowly.		\| intro = Prazosin is best known in psychiatry as an off-label treatment for PTSD nightmares, it suppresses noradrenergic hyperactivity at night and reduces both nightmare frequency and severity in many patients. Originally an antihypertensive; now more often prescribed in mental health than cardiology. First-dose orthostatic hypotension is well-known, start at 1 mg HS and titrate slowly.
	\| indications =		\| indications =
	\| dosing =		\| dosing =

MDElliottMD: Create Prazosin scaffold

2026-05-15T15:30:22Z

Create Prazosin scaffold

New page

{{MedTemplate
| generic = Prazosin
| brand = Minipress
| classes = Alpha-1 Adrenergic Antagonist
| uses = <vote slug="ptsd-nightmares-use">PTSD nightmares</vote>, <vote slug="hypertension-use">Hypertension</vote>, <vote slug="bph-use">BPH</vote>
| starting_dose = 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN)
| preparations = 1, 2, 5 mg caps
| fda_max = 40 mg/d
| routes = Oral
| onset = 30–90 min
| duration = 6–8 h
| halflife = 2–3 h
| bioavailability = ~60%
| pregnancy = Category C
| legal = Rx-only in US
| mechanism = Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares.
| intro = Prazosin is best known in psychiatry as an off-label treatment for PTSD nightmares — it suppresses noradrenergic hyperactivity at night and reduces both nightmare frequency and severity in many patients. Originally an antihypertensive; now more often prescribed in mental health than cardiology. First-dose orthostatic hypotension is well-known — start at 1 mg HS and titrate slowly.
| indications =
| dosing =
| effects =
| pk_absorption = ~60% oral bioavailability.
| pk_distribution = Plasma protein binding ~97%.
| pk_metabolism = Extensive hepatic metabolism.
| pk_elimination = Primarily fecal as metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Blood pressure (especially orthostatic) during titration.
| counseling = First-dose effect: marked orthostatic hypotension within 30–90 min. Take initial dose at bedtime. Rise slowly from supine. Effect on nightmares emerges in 1–3 weeks; titrate by 1–2 mg every few nights as needed.
| anecdotes =
| seealso = [[Clonidine]], [[Guanfacine]]
| references = <references/>
}}

[[Category:Medicines]]

Prazosin - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Create Prazosin scaffold